Sign In
Buy CRSP
$52.08
+0.0600 (+0.115%)
At Close: Jun 03, 2026
Is This News a Setback or a Step Forward for CRISPR Therapeutics?
02:00pm, Wednesday, 06'th Dec 2023
CRISPR Therapeutics is cutting two of its more advanced candidates in favor of two next-generation ones. The company is also awaiting a key regulatory decision on Friday.
CRISPR Therapeutics AG (CRSP) Up 20.5% Since Last Earnings Report: Can It Continue?
12:48pm, Wednesday, 06'th Dec 2023
CRISPR Therapeutics AG (CRSP) reported earnings 30 days ago. What's next for the stock?
CRISPR (CRSP) to Focus on Next-Generation CAR T Pipeline
02:17pm, Tuesday, 05'th Dec 2023
Based on early data from ongoing clinical studies, CRISPR (CRSP) has decided to focus on the development of its next-generation CAR T pipeline and discontinue its first-generation CAR T candidates.
Better Growth Stock: CRISPR Therapeutics vs. Invitae
05:00am, Tuesday, 05'th Dec 2023
CRISPR Therapeutics may soon generate its first product revenue. Invitae, making progress in its recovery plan, could climb if it meets its goals.
5 Top Stocks to Buy Before 2024
05:00am, Saturday, 02'nd Dec 2023
Now is a great time to consider stocks that may boost your portfolio, both in the new investing year and over time. Companies offering steady earnings growth -- or the promise of earnings growth -- ar
AI In Biotech: A Revolutionary Leap Forward Or Just Another Buzzword?
02:45pm, Friday, 01'st Dec 2023
AI isn't just revolutionizing biotech; it's reinventing it. From predicting diseases to accelerating drug discovery, AI is turning data into medical gold, reshaping how we approach healthcare innovati
5 Best Performing Stocks of the Top ETF of November
12:53pm, Friday, 01'st Dec 2023
ARK Innovation ETF (ARKK), which provides thematic multi-cap exposure to innovation across sectors, has gained 35.2%, becoming the best-performing ETF of November.
Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?
06:15am, Friday, 01'st Dec 2023
CRISPR and Vertex recently earned approval for a gene-editing treatment, Casgevy. Casgevy shows the potential of CRISPR's platform and should improve its financial results.
Looking for Growth? 2 Top Stocks to Buy Hand Over Fist
05:15am, Friday, 01'st Dec 2023
These companies are just getting started along the path of revenue growth. Their technologies -- gene editing and organism engineering -- help them stand out from the crowd.
3 Biotech Stocks That Could Be Multibaggers in the Making
09:37pm, Thursday, 30'th Nov 2023
In the dynamic realm of modern medicine, biotech stocks have effectively emerged at the forefront of a transformation. These innovative players are steering us towards a new era of medical marvels wit
Here's Why CRISPR Therapeutics AG (CRSP) is a Great Momentum Stock to Buy
01:33pm, Wednesday, 29'th Nov 2023
Does CRISPR Therapeutics AG (CRSP) have what it takes to be a top stock pick for momentum investors? Let's find out.
CRISPR Gene Editing: Intellia Vs. Crispr Therapeutics
12:20am, Wednesday, 29'th Nov 2023
Intellia Therapeutics and CRISPR Therapeutics are considered the top two players in the CRISPR space in the next 1 to 3 years. NTLA focuses on in vivo gene editing and has a comprehensive pipeline tar
Investing in These 3 Stocks Now Could Make You a Millionaire Retiree
05:50am, Saturday, 25'th Nov 2023
Amazon has plenty of room to grow despite its already huge size. CRISPR Therapeutics is at a pivotal point, with U.S. approvals for its lead candidate potentially on the way.
CRISPR-Cas9 Gene Editing Is On The Cusp Of Something Big
03:39am, Saturday, 25'th Nov 2023
Gene editing, also known as genome editing, allows scientists to modify the DNA of organisms using biotechnological techniques. CRISPR-Cas9 is the most widely used gene editing technology, known for i
CRISPR (CRSP) Rises More Than 40% in Past 3 Months: Here's Why
01:32pm, Friday, 24'th Nov 2023
CRISPR (CRSP) expects a potential approval for its gene-edited therapy, Casgevy (exa-cel) in the United States for treating two debilitating blood disorders. The drug has been recently approved in the
